The prevalence of diabetic nephropathy as a cause of end-stage renal disease (ESRD) in Egypt has been examined in small cross-sectional studies, with conflicting results. The need for a large-scale study prompted us to perform this 6-year multiple cross-sectional study. A sample of ESRD patients enrolled in the Egyptian renal data system was evaluated during the period 1996-2001 for the prevalence of diabetic nephropathy. Prevalence gradually increased from 8.9% in 1996, to 14.5% in 2001. The mean age of patients with diabetic nephropathy was significantly higher than that of patients with ESRD from other causes. Mortality was also significantly higher in diabetic patients with ESRD.

Adult↗

PubMedDate not supplied

Comparative studies on the effect of continuous intravenous infusion of some sulphonamides on blood and urine glucose levels in buffaloes.

Three groups of five clinically healthy buffaloes each were injected intravenously with sulphadiazine, sulphadimidine and sulphamerazine in a dose of 100 mg/kg b. wt. (as a singly initial dose of 40 mg/kg b. wt. an subsequently the plasma level kept constant by a continuous intravenous infusion of a maintenance dose of 20 mg/kg per hour over a period of 3 hours). It was found that, 1) sulphadiazine, sulphadimidine and sulphamerazine increase the plasma glucose levels at 1, 2, 2.5 and 3.5 hours from the start of i.v. infusion. 2) The glucose concentration in urine increased in the buffaloes infused i.v. with sulphadiazine. 3) The glucose level in urine of buffaloes infused i.v. with sulphadimidine and sulphamerazine was slightly increased. 4) The concentrations of sulphadiazine, sulphadimidine and sulphamerazine in plasma reached its highest level, 2.5, 2 and 2.5 hours during the i.v. infusion, respectively, then declined rapidly. 5) The concentrations of sulphadiazine, sulphadimidine and sulphamerazine in urine reached their highest concentrations 3.5 hours after i.v. infusion.

Animals↗